Psoriasis

At a recent Dermatology Times Case-Based Roundtable event, David Cotter, MD, PhD, reviewed treatment considerations for older patients with moderate to severe PsO who are candidates for biologic therapy.

The pharmaceutical companies announced an exclusive global license and transfer agreement for the advancement and commercialization of Spevigo.

Spesolimab effectively targets the IL-36 receptor, reducing inflammation and preventing flares in generalized pustular psoriasis, offering new hope for patients.

Although bimekizumab carries a precaution for suicidal ideation and behavior, current data suggest it may improve mental health outcomes for patients with psoriasis.

VYNE Therapeutics updates on VYN202, revealing promising early results in psoriasis treatment despite a clinical hold due to safety concerns.

A poster from SDPA 2025 showed brodalumab maintains a consistent safety profile with no completed suicides and low infection rates.

Subcutaneous spesolimab maintained durable GPP control for 12 months after rapid clearance from IV spesolimab in a high-risk elderly patient.

Remission is now defined as 0% BSA or IGA 0 for ≥6 months on treatment, per a Delphi consensus led by the National Psoriasis Foundation.

Explore the latest insights on IL-17 inhibitors for psoriasis, highlighting their mechanisms, real-world benefits, and future treatment strategies.

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

Aaron Farberg, MD, led a panel exploring the challenges of diagnosing and treating generalized pustular psoriasis and the promise of targeted therapies.

Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Celltrion's Yuflyma gains full FDA interchangeability, enhancing patient access and affordability for various inflammatory conditions.

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

A recent analysis reveals safety profiles of apremilast and deucravacitinib for psoriasis, highlighting unique adverse events and long-term monitoring needs.

Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearance for a phase 1 trial for mild to moderate psoriasis.

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

Psoriasis significantly impacts sleep health, with diverse populations facing increased risks of sleep disorders, highlighting urgent clinical needs for tailored interventions.

Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

New guidelines from the Genital Psoriasis Wellness Consortium highlight the significant impact of genital psoriasis on patients, emphasizing improved diagnosis and personalized treatment.

Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.

Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

Abrocitinib’s targeted inhibition of JAK1 offers effective control of AD, but may, in rare instances, lead to a shift in immune expression resulting in paradoxical psoriasis.

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Explore the potential of GLP-1 receptor agonists in psoriasis management, highlighting their immunomodulatory effects and metabolic benefits for patients.